OncoTricks

Small cell, pancreas, tumor lysis, ifosfamide and doxorubicin, Oct 6, 2026

Small cell lung cancer

The scenario: newly diagnosed extensive-stage disease, not yet treated, with a liver filling with metastases. Why we push to treat in the hospital, and what this patient can expect that a patient in 2016 could not.

If you remember one thingTreat now. A patient who gets through first-line chemotherapy today has a positive phase 3 trial waiting at every later step: maintenance, relapse, and (if limited stage) consolidation. The 10-month disease is now a 1-to-2-year disease for the patient who reaches each one.
2% → 12%

alive at 5 years, extensive stage

33 → 56 months

median survival, limited stage

8.3 → 13.6 months

median survival after relapse

What changed, in months of median survival

BeforeNow
First line, extensive stage. Clock starts at randomization, when treatment begins.
Platinum + etoposide
10.3
+ atezolizumab or durvalumab
12.3 to 13.0
Maintenance. Clock starts at randomization, after 4 cycles without progression.
Atezolizumab alone
10.6
+ lurbinectedin
13.2
Second line. Clock starts at randomization, after relapse.
Chemotherapy
8.3
Tarlatamab
13.6
Three charts above share one scale, 0 to 16 months. Each pair comes from one randomized trial, so compare within a pair, not across pairs.
Limited stage, after chemoradiation.
Observation
33.4
Durvalumab for 2 years
55.9
Limited stage uses its own scale, 0 to 60 months.

Medians from different trials cannot be added. The patient who reaches every step (induction, maintenance, tarlatamab at relapse) can reach 1.5 to 2 years; that is a sketch of the best case, not a trial number. Untreated, the historical series give 2 to 4 months, so with organ compromise or fast-moving symptoms, start in the hospital. Tell the patient "can reach", not "will live".

The trials behind each bar
TrialSettingWhat was addedMedian survivalHazard ratio
IMpower133 2018Extensive, first lineAtezolizumab to carboplatin + etoposide12.3 vs 10.3 mo0.70
CASPIAN 2019Extensive, first lineDurvalumab to platinum + etoposide13.0 vs 10.3 mo0.73
IMforte 2025Extensive, maintenanceLurbinectedin to atezolizumab13.2 vs 10.6 mo0.73
DeLLphi-304 2025Extensive, second lineTarlatamab instead of chemotherapy13.6 vs 8.3 mo0.60
ADRIATIC 2024Limited, after chemoradiationDurvalumab consolidation55.9 vs 33.4 mo0.73
DeLLphi-305 September 2026Extensive, maintenanceTarlatamab to durvalumabSurvival benefit announced by press release. Numbers not yet presented.

Name check: IMpower is the lung program. IMvigor is the same company's bladder program. Easy to swap at the bedside. And for tarlatamab: 304 is second line, 305 is maintenance.

Tarlatamab in five lines

What it is

A bispecific antibody. One arm grabs DLL3 on the tumor cell, the other grabs CD3 on a T cell, and the T cell kills what it touches. DLL3 is on most small cell tumors and almost no normal tissue.

How it is given

1 mg on day 1, 10 mg on days 8 and 15, then 10 mg every 2 weeks. Accelerated approval in May 2024, converted to full approval in November 2025 on the DeLLphi-304 survival data. Since September 2026 the first two doses need 6 to 8 hours of monitoring rather than an overnight stay, plus steroid premedication, a liter of saline afterward, a caregiver, 48 hours within an hour of the hospital, and a next-day check.

What you will be called for

Cytokine release in just over half, almost always in cycle 1: fever, sometimes mild hypotension. Confusion or word-finding trouble in about 1 in 10. Night float needs to know the patient got it.

Who actually benefits

In a US real-world cohort, patients who were up and about (ECOG 0 to 1) lived a median of 13.4 months. Those at ECOG 2 or worse lived 3.2. Retrospective data, but the message holds: protect function during first line. In DeLLphi-304 itself, tarlatamab also improved dyspnea and cough compared with chemotherapy.

Also on the horizon: ifinatamab deruxtecan, an antibody-drug conjugate against B7-H3, shrank tumors in 48% of pretreated patients in a phase 2 study. Its FDA application was withdrawn on September 25, 2026 pending the phase 3 trial.

The last brain MRI was two months ago. Why repeat it?

1. Two months is a long time in this disease

Small cell can double in weeks. Brain metastases are present in 10 to 20% at diagnosis and in more than half of patients by two years.

2. The result changes the order of treatment

Symptomatic brain metastases: steroids and radiation first. Small and silent: systemic therapy first, then re-image.

3. Surveillance needs a day-zero image

Preventive brain radiation did not beat MRI surveillance in a randomized trial (11.6 vs 13.7 months). If you follow with MRI every 3 months in the first year, you need a baseline to compare against.

4. Every future confusion gets compared to it

SIADH, opioids, liver failure, later neurotoxic drugs. When confusion comes, the first question is whether something in the brain is new.

Applying it at the bedside

  • Poor performance status from the cancer itself is a reason to treat small cell, not to hold. Response rates to platinum plus etoposide are 60 to 70%, and symptoms can improve quickly.
  • High bilirubin from liver metastases. Carboplatin is cleared by the kidney and keeps its dose. Etoposide has no formal liver dose rule in the label, but low albumin and high bilirubin both raise the free, active fraction, and this patient has both. Many reduce cycle 1 and go back up as bilirubin falls. Set the number with oncology pharmacy.
  • Immunotherapy from cycle 2. In the trials the checkpoint inhibitor started with cycle 1. For a patient treated urgently in the hospital, we give cycle 1 as chemotherapy alone and add it from cycle 2 as an outpatient.
  • Growth factor after cycle 1, tumor lysis labs every day, and a goals-of-care conversation in the same admission. These run in parallel with treatment, not after it.
Check yourself: two patients on durvalumab, our usual checkpoint inhibitor. One finished chemoradiation for limited-stage disease. The other finished 4 cycles of carboplatin and etoposide for extensive-stage disease. How long does each stay on it?

Limited stage: up to 24 months, then stop (ADRIATIC). Extensive stage: until progression or intolerance, no end date (CASPIAN). Same drug and dose. What changes is the stopping rule: a fixed course when the goal is cure, open-ended when the goal is control.

Lurbinectedin maintenance (IMforte) was tested with atezolizumab, not durvalumab. The durvalumab-based option is tarlatamab (DeLLphi-305), positive by press release and not yet approved.

Sources

Trial data retrieved from PubMed unless marked.

  1. Horn L, et al. IMpower133. N Engl J Med 2018. doi:10.1056/NEJMoa1809064
  2. Paz-Ares L, et al. CASPIAN. Lancet 2019. doi:10.1016/S0140-6736(19)32222-6
  3. Cheng Y, et al. ADRIATIC. N Engl J Med 2024. doi:10.1056/NEJMoa2404873
  4. Paz-Ares L, et al. IMforte. Lancet 2025. doi:10.1016/S0140-6736(25)01011-6
  5. Mountzios G, et al. DeLLphi-304. N Engl J Med 2025. doi:10.1056/NEJMoa2502099
  6. Petrelli F, et al. A decade of progress in small-cell lung cancer. Eur J Clin Pharmacol 2026. doi:10.1007/s00228-026-04119-2
  7. Barsouk AA, et al. Real-world tarlatamab outcomes by performance status. Clin Lung Cancer 2026. doi:10.1016/j.cllc.2026.07.001
  8. Mountzios G, et al. Patient-reported outcomes in DeLLphi-304. Lung Cancer 2026. doi:10.1016/j.lungcan.2026.109581
  9. Zambrano Iglesias MI, et al. Decoding small cell lung cancer. Cancers 2026. doi:10.3390/cancers18132173
  10. Takahashi T, et al. Prophylactic cranial irradiation vs observation. Lancet Oncol 2017. doi:10.1016/S1470-2045(17)30230-9
  11. Joel SP, et al. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996. doi:10.1200/JCO.1996.14.1.257
  12. Tarlatamab (Imdelltra) prescribing information, DailyMed (web). Label
  13. Etoposide injection prescribing information, DailyMed (web). Label
  14. Amgen press release, DeLLphi-305, September 2026 (web). Link
  15. CancerNetwork, ifinatamab deruxtecan application withdrawn, October 1, 2026 (web). Link